Quick Summary:
In an increasingly health-conscious global society, the demand for early detection methods and technologies continually strengthens. The anticipated value of the global in-vitro colorectal cancer screening tests market is projected to reach a staggering $1.1 billion by 2030, presenting a significant opportunity for companies within the medical industry to position themselves advantageously.
Our market research report provides in-depth analysis and insights into the key players in this burgeoning field including top competitors like Abbott Laboratories, Inc., Alere, Inc, and Exact Sciences Corporation. Moreover, it unveils critical data around global market trends and the potential growth in international markets including the U.S. and China. Making informed decisions in a rapidly innovating industry requires thorough research. Profit from our comprehensive report to stay ahead of market shifts and keep your finger on the pulse of the global In-Vitro Colorectal Cancer Screening Tests landscape.
Global In-Vitro Colorectal Cancer Screening Tests Market to Reach $1.1 Billion by 2030
The global market for In-Vitro Colorectal Cancer Screening Tests estimated at US$853.8 Million in the year 2022, is projected to reach a revised size of US$1.1 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2022-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is projected to record a 4% CAGR and reach US$881.5 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biomarker Test segment is readjusted to a revised 1.8% CAGR for the next 8-year period.
The U.S. Market is Estimated at $232.6 Million, While China is Forecast to Grow at 6.3% CAGR
The In-Vitro Colorectal Cancer Screening Tests market in the U.S. is estimated at US$232.6 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$233.4 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.9% and 4.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$149.5 Million by the year 2030.Select Competitors (Total 44 Featured) -
- Abbott Laboratories, Inc.
- Alere, Inc.
- Beckman Coulter, Inc.
- Clinical Genomics Technologies Pty Ltd.
- Eiken Chemical Co., Ltd.
- Epigenomics AG
- Exact Sciences Corporation
- Hemosure, Inc.
- Novigenix SA
- Quidel Corporation
- Sysmex Corporation
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for In-Vitro Colorectal Cancer Screening Tests?
What is the growth rate of the Global Market for In-Vitro Colorectal Cancer Screening Tests?
What is the forecasted size of the Global Market for In-Vitro Colorectal Cancer Screening Tests?
Who are the key companies in the Global Market for In-Vitro Colorectal Cancer Screening Tests?
| Report Attribute | Details |
|---|---|
| No. of Pages | 193 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 853.8 Million |
| Forecasted Market Value ( USD | $ 1100 Million |
| Compound Annual Growth Rate | 3.2% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Laboratories, Inc.
- Alere, Inc.
- Beckman Coulter, Inc.
- Clinical Genomics Technologies Pty Ltd.
- Eiken Chemical Co., Ltd.
- Epigenomics AG
- Exact Sciences Corporation
- Hemosure, Inc.
- Novigenix SA
- Quidel Corporation
- Sysmex Corporation
